Acticor Biotech announces the regulatory approval of the LIBERATE clinical trial, based on a long-standing collaboration with the University of Birmingham, to assess the safety and efficacy of glenzocimab in reducing the size of myocardial infarction.

This randomized, double-blind, placebo-controlled Phase 2b study will include over 200 patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention.

The study will be conducted at two UK hospitals: Queen Elizabeth Hospital, Birmingham, and Northern General Hospital, Sheffield. Patient recruitment is scheduled to begin by the end of 2023.

Copyright (c) 2023 CercleFinance.com. All rights reserved.